Scientists probe brain chemistry behind severe PMS to unlock better treatments
NCT ID NCT06704594
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how brain chemicals called neuroactive steroids change across the menstrual cycle in women with Premenstrual Dysphoric Disorder (PMDD) compared to healthy women. It also tests whether a low-dose antidepressant (sertraline) affects these chemical levels. The goal is to better understand what causes PMDD and how current treatments work, involving 288 women aged 18-50.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sertraline (an antidepressant)
- What this could lead to
- If successful, this could reveal why some women develop PMDD and how antidepressants help, pointing toward more targeted treatments.
- What could go wrong
- This is an early-stage, observational study focused on understanding mechanisms, not testing a new treatment. Results may not lead directly to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREMENSTRUAL DYSPHORIC DISORDER ( PMDD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Reproductive Mental Health Center
RECRUITINGBaltimore, Maryland, 21205, United States
-
University of Virginia
RECRUITINGCharlottesville, Virginia, 22903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.